Insys Planning To Sell Off Opioid-Related Assets, Following Settlement In Federal Investigation

Potential sell-off plans include Insys' Subsys, a mouth-spray version of the fentanyl painkiller, and formulations of buprenorphine. In other pharma news, the FDA continues to find quality control problems at Akorn manufacturing plants.

from Kaiser Health News https://ift.tt/2zvO9Bz